 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Project Inform
In the Dog House: ChironJanuary 2003
This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Project Inform
In the Dog House: ChironJanuary 2003
This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. |
E-Mail
Printable Single-Page
Glossary
PDF
Share
Chiron Corporation, maker of interleukin-2 (IL-2), the most promising immunotherapy for HIV, for dropping the most important study of the drug without completing it. The company has given various excuses and reasons, but the bottom line is money and an intention to become less involved in HIV. Negotiations are underway to revive a streamlined version of the study, but Chiron continues to offer less financial support than needed.
